BACIT : Fact Sheet – 26 September 2016 Download .pdf

Share Price

-0.58%

0.20%

0.59%

1.25

NAV Total Return

1.51%

2.05%

0.85%

1.20

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

YTD

2016

-2.19

-0.41

0.08

0.08

1.30

-1.46

2.01

1.51

-

-

-

-

0.85

2015

2.73

1.01

3.58

-0.16

1.53

-2.56

2.15

-2.07

-2.13

1.60

2.39

1.44

9.69

2014

-0.55

0.58

0.13

-1.64

2.18

-0.20

-0.51

0.26

0.58

0.17

2.36

0.55

3.91

2013

4.12

2.55

2.58

-0.16

2.69

-1.57

1.24

-1.23

-0.78

2.94

-0.42

0.82

13.32

2012

-

-

-

-

-

-

-

-

-

-

0.53

2.34

2.89

Structure Closed End Investment Company

Fund

Investment Manager

Strategy

Asset

% of

Domicile Guernsey

Class

NAV

Listing London Stock Exchange

1 Polygon European Equity Opportunity

Polygon Global Partners

Hedge

Equities

6.4%

Website www.bacitltd.com

2 Polar Capital Japan Alpha

Polar Capital

Long Bias

Equities

6.1%

Investment Manager BACIT (UK)Limited

3 Majedie UK Equity

Majedie Asset Management

Long Bias

Equities

5.9%

Administrator Northern Trust International

4 Tower Master Fund

Ten Five Capital Management

Hedge

Equities

5.1%

Custodian Northern Trust (Guernsey) Ltd

5 Maga Smaller Companies UCITS

Otus Capital Management

Hedge

Equities

5.0%

Registrar Capita Registrars (Guernsey) Limited

6 Sinfonietta

Symphony Financial Partners

Hedge

Macro

5.0%

Corporate Broker J.P. Morgan Cazenove

7 Parity Value

Parity Asset Management Limited

Hedge

Macro

4.9%

8 SW Mitchell European

SW Mitchell Capital

Hedge

Equities

4.5%

9 Polygon Mining

Polygon Global Partners

Hedge

Equities

4.4%

10 The SFP Value Realization Fund

Symphony Financial Partners

Long Bias

Equities

4.3%

Total

51.5%

CHARITIES SUPPORTED BY BACIT

BACIT Limited

ASSET ALLOCATION (% OF NAV)

FUND STRATEGY ALLOCATION (% OF NAV)

CashCommodi

Private Equity 1%5%

6%

Macro

13%

Infrastructure

3%

Fixed Income

4%

Equity Long Bias

20%

DENOMINATION OF INVESTMENTS (% OF NAV)

ty

Credit

11%

Equity Hedge 37%

Cash

1%

Long Bias

36%

Infrastructure

3%

STRATEGY GEOGRAPHICAL FOCUS (% OF NAV)

Hedge

60%

US$ Partially Hedged into GBP, € Hedged into GBP, SEK Unhedged

Cash

1%Emerging

EUR (hedged) 10%

USD (hedged) 15% Asia-Pacific 15%

26%

US

6%

UK

6%

GBP

29% Europe

41%

Global

10%

USD

29% SEK Europe & US

1% 11%

NAV PERFORMANCE ANALYSIS ALLOCATION LIMITS

Inception

26 October 2012

Current

Limit

% of

NAV (£m)

£479.7

Limit

1 Month Return

1.51%

Asset Class

Equity Hedge

37%

80%

46%

3 Month Return

2.05%

Manager

Polygon Global Partners

13%

30%

45%

YTD Return

0.85%

Fund

Polygon European Equity Opportunity

6%

20%

32%

Last 12 Months Return

4.16%

NAV Total Return Since Inception

34.02%

INDEX ANALYSIS OF NAV PERFORMANCE

Annualised Return Since Inception

7.94%

Annualised Volatility Since Inception

5.73%

Monthly comparative MSCI World

FT All-Share

HFRIFOFS

Sharpe Ratio

1.3

(TR, $)

(TR, £)

Index

Best Month

4.12%

Alpha

6%

5%

5%

Worst Month

-2.56%

Beta

0.22

0.34

0.76

% Positive Months

65%

Correlation

0.43

0.60

0.64

Largest Drawdown

-4.59%

Outperformance in Down Markets*

88%

94%

67%

*This measures the percentage of months when the benchmark falls, that BACIT outperforms it.

DATA SOURCES:

Data has been sourced from Bloomberg, Northern Trust, the Company's administrator, and the underlying funds.

IMPORTANT INFORMATION AND LEGAL DISCLAIMER

This fact sheet contains information regarding BACIT Limited's (the "Company's") performance and outlook. The information contained in the fact sheet is unaudited, and the reported NAVs of the underlying funds may have been subject to deductions in respect of management and performance fees which will not apply to the Company's investment. This fact sheet is provided for information purposes only and does not constitute an invitation or offer to subscribe for or purchase shares in the Company. The material provided is not intended to provide a sufficient basis on which to make an investment decision. Past performance is no guarantee of future returns and estimated results, performance or achievements may materially differ from actual results. All investments are subject to risk. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decisions.

Information and opinions presented in the material contained on these pages relating to the Company and its investments have been obtained or derived from sources believed by the Company to be reliable, but the Company makes no representation as to their accuracy or completeness. Except as required by applicable law, the Company expressly disclaims any obligations to update or revise such estimates to reflect any change in expectations, new information, subsequent events or otherwise.

Alzheimer's Research UK

£128,460

The Alzheimer's Society

£111,969

Beating Bowel Cancer

£111,866

Butterfly Thyroid Cancer Trust

£111,927

Child Bereavement UK

£123,806

Cure Leukaemia

£111,877

Downside Up

£125,534

The Egmont Trust

£111,855

The Institute of Cancer Research

£148,216

The James Wentworth-Stanley Memorial Fund

£123,706

JDRF

£111,862

The Louis Dundas Centre for Children's Palliative Care

£126,662

Maggie's

£116,609

Marie Curie

£114,036

NSPCC

£116,551

The Rwanda Hope Foundation

£111,861

Scope

£111,918

SSAFA

£111,927

Supporting Wounded Veterans

£123,817

Women for Women International

£116,543